Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3% - What's Next?

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report)'s share price dropped 5.3% during trading on Friday . The stock traded as low as $9.55 and last traded at $9.56. Approximately 41,906 shares traded hands during trading, a decline of 93% from the average daily volume of 612,849 shares. The stock had previously closed at $10.09.

Wall Street Analyst Weigh In

ATXS has been the subject of a number of research analyst reports. Oppenheimer lifted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a research note on Thursday. Evercore ISI upgraded shares of Astria Therapeutics to a "strong-buy" rating in a research note on Wednesday, August 14th. TD Cowen initiated coverage on Astria Therapeutics in a research note on Monday, July 29th. They issued a "buy" rating and a $35.00 price target for the company. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday. Finally, Wedbush reaffirmed an "outperform" rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $25.60.

Astria Therapeutics Stock Down 7.1 %

The firm's 50 day moving average is $11.40 and its two-hundred day moving average is $10.61. The stock has a market cap of $528.66 million, a price-to-earnings ratio of -4.48 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, analysts anticipate that Astria Therapeutics, Inc. will post -1.68 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

Several hedge funds have recently bought and sold shares of ATXS. Quest Partners LLC increased its stake in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 3,112 shares during the period. Ameritas Investment Partners Inc. increased its position in Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company's stock valued at $70,000 after acquiring an additional 2,861 shares during the period. PDT Partners LLC bought a new stake in Astria Therapeutics during the 3rd quarter valued at $140,000. SG Americas Securities LLC acquired a new position in Astria Therapeutics during the 3rd quarter worth $155,000. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of Astria Therapeutics in the first quarter worth $200,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.